{
  "guideline": {
    "id": "PA166104829",
    "name": "Annotation of FDA Label for tetrabenazine and CYP2D6",
    "source": "FDA",
    "version": 28,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166104829",
    "relatedChemicals": [
      {
        "id": "PA140222719",
        "name": "tetrabenazine",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA128",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "symbol": "CYP2D6"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166309041",
      "name": "Recommendation Annotation PA166309041",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA140222719",
          "name": "tetrabenazine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452198060,
        "html": "<p>&quot;In [CYP2D6] PMs, the initial dose and titration is similar to EMs except that the recommended maximum single dose is 25 mg, and the recommended daily dose should not exceed a maximum of 50 mg.&quot; See label for more information</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166309043",
      "name": "Recommendation Annotation PA166309043",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA140222719",
          "name": "tetrabenazine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452198062,
        "html": "<p>&quot;Genotyped patients who are identified as extensive (EMs) or intermediate metabolizers (IMs) of\nCYP2D6, who need doses of XENAZINE [tetrabenazine] above 50 mg per day, should be titrated up slowly at\nweekly intervals by 12.5 mg daily, to allow the identification of a tolerated dose that reduces\nchorea. Doses above 50 mg per day should be given in a three times a day regimen. The\nmaximum recommended daily dose is 100 mg and the maximum recommended single dose is\n37.5 mg. If adverse reactions such as akathisia, parkinsonism, depression, insomnia, anxiety or\nsedation occur, titration should be stopped and the dose should be reduced. If the adverse\nreaction does not resolve, consideration should be given to withdrawing XENAZINE [tetrabenazine] treatment\nor initiating other specific treatment.&quot; See label for more information</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "0.75"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166309045",
      "name": "Recommendation Annotation PA166309045",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA140222719",
          "name": "tetrabenazine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452198064,
        "html": "<p>&quot;Genotyped patients who are identified as extensive (EMs) or intermediate metabolizers (IMs) of\nCYP2D6, who need doses of XENAZINE [tetrabenazine] above 50 mg per day, should be titrated up slowly at\nweekly intervals by 12.5 mg daily, to allow the identification of a tolerated dose that reduces\nchorea. Doses above 50 mg per day should be given in a three times a day regimen. The\nmaximum recommended daily dose is 100 mg and the maximum recommended single dose is\n37.5 mg. If adverse reactions such as akathisia, parkinsonism, depression, insomnia, anxiety or\nsedation occur, titration should be stopped and the dose should be reduced. If the adverse\nreaction does not resolve, consideration should be given to withdrawing XENAZINE [tetrabenazine] treatment\nor initiating other specific treatment.&quot; See label for more information</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "1.25"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166309047",
      "name": "Recommendation Annotation PA166309047",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA140222719",
          "name": "tetrabenazine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452198066,
        "html": "<p>&quot;Genotyped patients who are identified as extensive (EMs) or intermediate metabolizers (IMs) of\nCYP2D6, who need doses of XENAZINE [tetrabenazine] above 50 mg per day, should be titrated up slowly at\nweekly intervals by 12.5 mg daily, to allow the identification of a tolerated dose that reduces\nchorea. Doses above 50 mg per day should be given in a three times a day regimen. The\nmaximum recommended daily dose is 100 mg and the maximum recommended single dose is\n37.5 mg. If adverse reactions such as akathisia, parkinsonism, depression, insomnia, anxiety or\nsedation occur, titration should be stopped and the dose should be reduced. If the adverse\nreaction does not resolve, consideration should be given to withdrawing XENAZINE [tetrabenazine] treatment\nor initiating other specific treatment.&quot; See label for more information</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "1.75"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166309049",
      "name": "Recommendation Annotation PA166309049",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA140222719",
          "name": "tetrabenazine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452198068,
        "html": "<p>&quot;Genotyped patients who are identified as extensive (EMs) or intermediate metabolizers (IMs) of\nCYP2D6, who need doses of XENAZINE [tetrabenazine] above 50 mg per day, should be titrated up slowly at\nweekly intervals by 12.5 mg daily, to allow the identification of a tolerated dose that reduces\nchorea. Doses above 50 mg per day should be given in a three times a day regimen. The\nmaximum recommended daily dose is 100 mg and the maximum recommended single dose is\n37.5 mg. If adverse reactions such as akathisia, parkinsonism, depression, insomnia, anxiety or\nsedation occur, titration should be stopped and the dose should be reduced. If the adverse\nreaction does not resolve, consideration should be given to withdrawing XENAZINE [tetrabenazine] treatment\nor initiating other specific treatment.&quot; See label for more information</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "2.25"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166309042",
      "name": "Recommendation Annotation PA166309042",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA140222719",
          "name": "tetrabenazine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452198061,
        "html": "<p>&quot;Genotyped patients who are identified as extensive (EMs) or intermediate metabolizers (IMs) of\nCYP2D6, who need doses of XENAZINE [tetrabenazine] above 50 mg per day, should be titrated up slowly at\nweekly intervals by 12.5 mg daily, to allow the identification of a tolerated dose that reduces\nchorea. Doses above 50 mg per day should be given in a three times a day regimen. The\nmaximum recommended daily dose is 100 mg and the maximum recommended single dose is\n37.5 mg. If adverse reactions such as akathisia, parkinsonism, depression, insomnia, anxiety or\nsedation occur, titration should be stopped and the dose should be reduced. If the adverse\nreaction does not resolve, consideration should be given to withdrawing XENAZINE [tetrabenazine] treatment\nor initiating other specific treatment.&quot; See label for more information</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166309044",
      "name": "Recommendation Annotation PA166309044",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA140222719",
          "name": "tetrabenazine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452198063,
        "html": "<p>&quot;Genotyped patients who are identified as extensive (EMs) or intermediate metabolizers (IMs) of\nCYP2D6, who need doses of XENAZINE [tetrabenazine] above 50 mg per day, should be titrated up slowly at\nweekly intervals by 12.5 mg daily, to allow the identification of a tolerated dose that reduces\nchorea. Doses above 50 mg per day should be given in a three times a day regimen. The\nmaximum recommended daily dose is 100 mg and the maximum recommended single dose is\n37.5 mg. If adverse reactions such as akathisia, parkinsonism, depression, insomnia, anxiety or\nsedation occur, titration should be stopped and the dose should be reduced. If the adverse\nreaction does not resolve, consideration should be given to withdrawing XENAZINE [tetrabenazine] treatment\nor initiating other specific treatment.&quot; See label for more information</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166309046",
      "name": "Recommendation Annotation PA166309046",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA140222719",
          "name": "tetrabenazine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452198065,
        "html": "<p>&quot;Genotyped patients who are identified as extensive (EMs) or intermediate metabolizers (IMs) of\nCYP2D6, who need doses of XENAZINE [tetrabenazine] above 50 mg per day, should be titrated up slowly at\nweekly intervals by 12.5 mg daily, to allow the identification of a tolerated dose that reduces\nchorea. Doses above 50 mg per day should be given in a three times a day regimen. The\nmaximum recommended daily dose is 100 mg and the maximum recommended single dose is\n37.5 mg. If adverse reactions such as akathisia, parkinsonism, depression, insomnia, anxiety or\nsedation occur, titration should be stopped and the dose should be reduced. If the adverse\nreaction does not resolve, consideration should be given to withdrawing XENAZINE [tetrabenazine] treatment\nor initiating other specific treatment.&quot; See label for more information</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "1.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166309048",
      "name": "Recommendation Annotation PA166309048",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA140222719",
          "name": "tetrabenazine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452198067,
        "html": "<p>&quot;Genotyped patients who are identified as extensive (EMs) or intermediate metabolizers (IMs) of\nCYP2D6, who need doses of XENAZINE [tetrabenazine] above 50 mg per day, should be titrated up slowly at\nweekly intervals by 12.5 mg daily, to allow the identification of a tolerated dose that reduces\nchorea. Doses above 50 mg per day should be given in a three times a day regimen. The\nmaximum recommended daily dose is 100 mg and the maximum recommended single dose is\n37.5 mg. If adverse reactions such as akathisia, parkinsonism, depression, insomnia, anxiety or\nsedation occur, titration should be stopped and the dose should be reduced. If the adverse\nreaction does not resolve, consideration should be given to withdrawing XENAZINE [tetrabenazine] treatment\nor initiating other specific treatment.&quot; See label for more information</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "2.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166309061",
      "name": "Recommendation Annotation PA166309061",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA140222719",
          "name": "tetrabenazine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452198080,
        "html": "<p>&quot;Genotyped patients who are identified as extensive (EMs) or intermediate metabolizers (IMs) of\nCYP2D6, who need doses of XENAZINE [tetrabenazine] above 50 mg per day, should be titrated up slowly at\nweekly intervals by 12.5 mg daily, to allow the identification of a tolerated dose that reduces\nchorea. Doses above 50 mg per day should be given in a three times a day regimen. The\nmaximum recommended daily dose is 100 mg and the maximum recommended single dose is\n37.5 mg. If adverse reactions such as akathisia, parkinsonism, depression, insomnia, anxiety or\nsedation occur, titration should be stopped and the dose should be reduced. If the adverse\nreaction does not resolve, consideration should be given to withdrawing XENAZINE [tetrabenazine] treatment\nor initiating other specific treatment.&quot; See label for more information</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "0.25"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product tetrabenazine (tetrabenazine), NDA021894, Oceanside Pharmaceuticals",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021894"
    }
  ],
  "version": "2024-02-29-20-19"
}